• HyperPFU™ high-fidelity DNA polymerase: Practical PCR Guidan

  2026-07-22

  HyperPFU™ high-fidelity DNA polymerase is engineered for the reliable PCR amplification of long, GC-rich, or otherwise challenging DNA templates, where standard enzymes often fail due to low fidelity or processivity. It is best used for workflows demanding blunt-ended, high-accuracy products, such as cloning and high-throughput sequencing, but is not suitable for applications requiring 3'-A overhangs or sticky-end generation.

• Distinct Mechanisms of PARP1 Regulation by RSL3 in Ferroptos

  2026-07-22

  This study reveals that RSL3, a classical ferroptosis inducer, promotes apoptosis by modulating PARP1 via both caspase-dependent cleavage and inhibition of m6A-mediated translation. The findings illuminate previously unappreciated pathways of cell death integration, with direct implications for targeting PARPi-resistant tumors.

• Malate’s Strategic Role in TCA Cycle Research and Tumor Immu

  2026-07-21

  This thought-leadership article explores the mechanistic and translational significance of malate ((S)-2-hydroxysuccinic acid) in dissecting the metabolic-immune axis of cancer, particularly in the context of PDHA1 succinylation-driven immune evasion in cholangiocarcinoma. We bridge foundational TCA cycle biochemistry with innovative experimental workflows, discussing malate’s value as a research reagent and providing actionable guidance for translational investigators.

• T7 RNA Polymerase: Optimizing In Vitro Transcription Workflo

  2026-07-21

  T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, is revolutionizing in vitro transcription for applications from RNA vaccine production to RNAi research. This guide delivers actionable workflow enhancements, troubleshooting strategies, and data-driven insights, drawing on recent advances in self-amplifying RNA vaccines and practical research experiences.

• LDH Cytotoxicity Assay Kit: Precision in Cell Cytotoxicity M

  2026-07-20

  The LDH Cytotoxicity Assay Kit empowers researchers with a non-radioactive, highly sensitive platform for quantifying cell cytotoxicity and apoptosis. Its versatility and robust design make it ideal for cancer research, neurodegenerative disease models, and advanced biocompatibility assessments.

• Trichostatin A (TSA): Unveiling HDAC3–Ferroptosis Axis in Ca

  2026-07-20

  Explore how Trichostatin A (TSA), a potent HDAC inhibitor, uniquely enables interrogation of the HDAC3–NRF2–GPX4 ferroptosis pathway and cell cycle regulation in cancer. This article offers advanced insights and practical guidance for researchers seeking to exploit epigenetic vulnerabilities in oncology.

• HyperPFU™ high-fidelity DNA polymerase: Technical Use Guide

  2026-07-19

  HyperPFU™ high-fidelity DNA polymerase addresses the technical challenges of amplifying long, GC-rich, or otherwise difficult DNA templates with high fidelity and speed. It is ideal for workflows requiring blunt-ended, accurate PCR products, such as cloning and high-throughput sequencing, but should not be used when 3'-A overhangs or sticky ends are necessary.

• Enabling mRNA-Based Tumor Suppressor Therapy: ATP Solution i

  2026-07-18

  This article unpacks the mechanistic and strategic value of high-purity ATP Solution (100 mM) in the development and optimization of mRNA-based tumor suppressor therapies for bladder cancer. Drawing on recent advances in lipid nanoparticle-mediated p21 mRNA delivery, we bridge cutting-edge biological rationale with actionable guidance for translational researchers, highlighting how APExBIO’s ATP Solution enables reproducibility and precision in sensitive kinase, transcription, and phosphorylation workflows critical to next-generation cancer therapeutics.

• Q-VD-OPh: Pan-Caspase Inhibitor Workflows for Apoptosis Rese

  2026-07-17

  Q-VD-OPh empowers researchers to dissect apoptosis mechanisms with precision, offering robust caspase inhibition in both in vitro and in vivo systems. Its cell-permeable, irreversible action not only advances fundamental studies but also improves viability in sensitive applications like cryopreservation and neurodegenerative modeling.

• Docetaxel in Cancer Chemotherapy Research: Applied Workflows

  2026-07-17

  Docetaxel (Taxotere) sets a gold-standard in cancer chemotherapy research, enabling precise apoptosis induction and chemoresistance studies across breast, ovarian, and gastric cancer models. This article delivers advanced workflow guidance, troubleshooting insights, and actionable protocol parameters, translating recent gene network findings into bench-ready strategies.

• Yeast-Engineered Exendin-4: Expanding Access to Diabetes Res

  2026-07-16

  This study demonstrates stable chromosomal expression of Exendin-4 in Saccharomyces cerevisiae, enabling cost-effective, scalable production of a key GLP-1 receptor agonist for type 2 diabetes research. The platform addresses critical barriers to medication accessibility and lays groundwork for both local manufacturing and novel research workflows.

• T7 RNA Polymerase: Strategic Leverage for Translational RNA

  2026-07-16

  Explore the strategic and mechanistic role of T7 RNA Polymerase—a recombinant enzyme expressed in E. coli—in advancing translational RNA research, with actionable guidance for researchers designing in vitro transcription, RNA vaccine production, and RNAi workflows. This thought-leadership article bridges molecular insight with translational opportunity, contextualizing APExBIO’s T7 RNA Polymerase within the current landscape and referencing landmark studies to inform best practices.

• Lovastatin as an HMG-CoA Reductase Inhibitor: Applied Protoc

  2026-07-15

  Lovastatin’s nanomolar potency as an HMG-CoA reductase inhibitor makes it a trusted tool for probing cholesterol metabolism, apoptosis, and cancer cell biology. This article translates current research and product guidance into actionable protocols, troubleshooting strategies, and comparative insights for advanced laboratory workflows.

• Inducing Right Ventricular Cardiomyocytes from Human PSCs

  2026-07-15

  Saito et al. present a modified differentiation protocol enabling specific induction of right ventricular-like cardiomyocytes from human pluripotent stem cells. This advance provides a foundation for chamber-specific cardiac disease modeling and drug testing, addressing a significant gap in translational cardiac research.

• Collagen VI-Enhanced ECM Scaffolds Advance Islet Organoid Ma

  2026-07-14

  This study demonstrates that decellularized amniotic membrane (dAM) hydrogels enriched with collagen VI significantly promote the viability, architectural fidelity, and functional maturation of iPSC-derived islet organoids. These findings offer a robust platform for improving diabetes cell therapy and provide insight into extracellular matrix optimization for organoid engineering.

16951 records 1/1131 page Next 12345 下5页 Last page